$ADIL
Adial Pharmaceuticals Inc Stock $adil

$adil Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024028701 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.391M	$1.519M	$5.621M
YoY Change	-38.03%	-27.75%	-38.5%
% of Gross Profit
Research & Development	$454.3K	$264.4K	$1.267M
YoY Change	-32.84%	-76.74%	-69.67%
% of Gross Profit
Depreciation & Amortization	$140.00	$560.00	$560.00
YoY Change	-93.24%	-73.08%	-93.24%
% of Gross Profit
Operating Expenses	$1.845M	$1.784M	$6.888M
YoY Change	-36.83%	-44.94%	-48.28%
Operating Profit	-$1.845M		-$6.888M
YoY Change	-36.83%		-48.28%
Interest Expense	-$167.1K	-$182.7K	-$124.1K
YoY Change	-678.3%	-481.97%	-296.35%
% of Operating Profit
Other Income/Expense, Net	-$4.632M	$62.06K	$10.16K
YoY Change	-31200.85%	-80.9%	-98.26%
Pretax Income	-$6.477M	-$1.904M	-$7.002M
YoY Change	122.88%	-33.58%	-45.01%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.477M	-$1.920M	-$5.123M
YoY Change	122.88%	-33.01%	-59.76%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.19		-$3.60
Diluted Earnings Per Share	-$2.19	-$1.34	-$3.59
COMMON SHARES
Basic Shares Outstanding	4.055M shares	1.218M shares
Diluted Shares Outstanding	2.954M shares		1.425M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.025M	$2.827M	$2.827M
YoY Change	117.29%	-29.35%	-29.35%
Cash & Equivalents	$5.025M	$2.827M	$2.827M
Short-Term Investments
Other Short-Term Assets	$311.4K	$371.6K	$371.6K
YoY Change	-52.25%	-52.25%	-52.25%
Inventory
Prepaid Expenses	$36.00K
Receivables
Other Receivables
Total Short-Term Assets	$5.336M	$3.199M	$3.199M
YoY Change	80.0%	-33.08%	-33.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$3.772K	$3.913K
YoY Change
Long-Term Investments	$1.344M	$1.534M	$1.534M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.348M	$1.538M	$1.538M
YoY Change	43.85%	61.4%	61.4%
TOTAL ASSETS
Total Short-Term Assets	$5.336M	$3.199M	$3.199M
Total Long-Term Assets	$1.348M	$1.538M	$1.538M
Total Assets	$6.684M	$4.737M	$4.737M
YoY Change	71.32%	-17.38%	-17.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$177.5K	$127.4K	$127.4K
YoY Change	-66.52%	-67.65%	-67.65%
Accrued Expenses	$375.3K	$525.7K	$525.7K
YoY Change	-68.31%	-54.48%	-62.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$562.7K	$653.1K	$653.1K
YoY Change	-68.7%	-63.53%	-63.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$562.7K	$653.1K	$653.1K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$562.7K	$653.1K	$653.1K
YoY Change	-77.14%	-73.41%	-73.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.27M	-$68.80M
YoY Change	13.06%	8.05%
Common Stock	$4.054K	$1.663K
YoY Change	-85.78%	-93.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.122M	$4.084M	$4.084M
YoY Change
Total Liabilities & Shareholders Equity	$6.684M	$4.737M	$4.737M
YoY Change	71.32%	-17.38%	-17.38%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.477M	-$1.920M	-$5.123M
YoY Change	122.88%	-33.01%	-59.76%
Depreciation, Depletion And Amortization	$140.00	$560.00	$560.00
YoY Change	-93.24%	-73.08%	-93.24%
Cash From Operating Activities	-$1.626M	-$1.227M	-$6.807M
YoY Change	-29.26%	-29.93%	-39.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$350.0K	$1.500M
YoY Change
Cash From Investing Activities		$350.0K	$1.500M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$4.132M
YoY Change			-54.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.824M	3.382M	4.132M
YoY Change	527.33%		-54.72%
NET CHANGE
Cash From Operating Activities	-$1.626M	-1.227M	-6.807M
Cash From Investing Activities		350.0K	1.500M
Cash From Financing Activities	$3.824M	3.382M	4.132M
Net Change In Cash	$2.198M	2.505M	-1.175M
YoY Change	-230.12%	-243.09%	-42.99%
FREE CASH FLOW
Cash From Operating Activities	-$1.626M	-$1.227M	-$6.807M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1001505	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1424661	shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38323
CY2023	dei	Entity Registrant Name EntityRegistrantName	ADIAL PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q4	us-gaap	Liabilities Liabilities	2456310	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3074668
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4870 Sadler Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Glen Allen
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23060
CY2023	dei	City Area Code CityAreaCode	(804)
CY2023	dei	Local Phone Number LocalPhoneNumber	487-8196
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	ADIL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5385155	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4054861	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum llp
CY2023	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2827082	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4001794	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	371597	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	349441	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	428700	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3198679	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4779935	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3913	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4477	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1534013	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	948392	usd
CY2023Q4	us-gaap	Assets Assets	4736605	usd
CY2022Q4	us-gaap	Assets Assets	5732804	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	103325	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	276410	usd
CY2023Q4	adil	Accounts Payable Related Party Currrent AccountsPayableRelatedPartyCurrrent	24062	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	477747	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	963327	usd
CY2023Q4	adil	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	47942	usd
CY2022Q4	adil	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	175000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10387	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	365742	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	653076	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1790866	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	665444	usd
CY2023Q4	us-gaap	Liabilities Liabilities	653076	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1663421	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1663421	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1067491	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1067491	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1663	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1067	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72879738	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66949958	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68797872	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63674531	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4083529	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3276494	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4736605	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5732804	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1267077	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1950308	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5620870	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8909167	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6887947	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	10859475	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6887947	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10859475	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	69779	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	63338	usd
CY2023	adil	Loss On Equity Method Investment LossOnEquityMethodInvestment	-193884	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10162	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-113943	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	63338	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7001890	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10796137	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7001890	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10796137	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	1878549	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1935279	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5123341	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12731416	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-4.91
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-10.78
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	1.32
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-1.93
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.6
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.71
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1424661	shares
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1001505	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2101210	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1273283	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	9123741	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1865	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12731416	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3276494	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1232691	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	513687	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	51901	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1661	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	749943	usd
CY2023	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3383312	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	503	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5123341	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4083529	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7001890	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10796137	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1746378	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3374493	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	564	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	564	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	51901	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-193884	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-9931	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	22156	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-40060	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-485580	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1413603	usd
CY2023	adil	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	-127058	usd
CY2022	adil	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	175000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-183473	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15826	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	24062	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5803368	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8593866	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1003441	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-2592119	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6806809	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11185985	usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1500000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1500000	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	749943	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	9123741	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3383312	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	503	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1865	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1661	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4132097	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9125606	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1174712	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2060379	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4001794	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6062173	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2827082	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4001794	usd
CY2023	adil	Equity Consideration Received For Sale Of Purnovate EquityConsiderationReceivedForSaleOfPurnovate	1727897	usd
CY2023Q4	adil	Gain On Sale GainOnSale	2624798	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1500000	usd
CY2023	us-gaap	Payment For Management Fee PaymentForManagementFee	450000	usd
CY2023	us-gaap	Proceeds From Payments For Securities Purchased Under Agreements To Resell ProceedsFromPaymentsForSecuritiesPurchasedUnderAgreementsToResell	1050000.00	usd
CY2023Q4	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3400000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of these consolidated financial statements in conformity with GAAP requires Company management to make estimates and assumptions the affect the amounts of assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results might differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant items subject to such estimates and assumptions include accruals associated with third party providers supporting clinical trials, income tax asset realization, and the valuation of equity method investments.</p>
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3251008	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	483834	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	152194	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	172679	shares
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	26664	shares
CY2022	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	43333	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3429866	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	699846	shares
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	927000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1600000	usd
CY2023Q2	us-gaap	Payments For Fees PaymentsForFees	450000	usd
CY2023Q2	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	1050000	usd
CY2023Q4	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	1050000	usd
CY2023Q3	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	1050000	usd
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	1727897	usd
CY2023Q4	adil	Total Consideration Paid TotalConsiderationPaid	3227897	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	800000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1727897	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Assets DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets	700000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	3227897	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Current DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent	48492	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	455000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Current DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent	248971	usd
CY2023Q4	adil	Disposal Group Including Discontinued Operation Goodwill Current Operating Lease Rightofuse Asset DisposalGroupIncludingDiscontinuedOperationGoodwillCurrentOperatingLeaseRightofuseAsset	180229	usd
CY2023Q4	adil	Disposal Group Including Discontinued Operation Inventory Current Deposits And Prepaid Expenses DisposalGroupIncludingDiscontinuedOperationInventoryCurrentDepositsAndPrepaidExpenses	428700	usd
CY2023Q4	adil	Disposal Group Including Discontinued Operation Total Assets Sold DisposalGroupIncludingDiscontinuedOperationTotalAssetsSold	1361392	usd
CY2023Q4	adil	Disposal Group Including Discontinued Operation Contingent Liability DisposalGroupIncludingDiscontinuedOperationContingentLiability	506000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Deferred Revenue Current DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent	193796	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent	58497	usd
CY2023Q4	adil	Disposal Group Including Discontinued Operation Accounts Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationAccountsLiabilitiesTransferred	758293	usd
CY2023Q4	adil	Disposal Group Including Discontinued Operation Net Assets Sold DisposalGroupIncludingDiscontinuedOperationNetAssetsSold	603099	usd
CY2023Q2	us-gaap	Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee	0.15	pure
CY2023Q2	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	4000000	usd
CY2023Q4	us-gaap	Equity Issued In Business Combination Fair Value Disclosure EquityIssuedInBusinessCombinationFairValueDisclosure	1727897	usd
CY2023	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Equity Interests BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests	1727897	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	193884	usd
CY2022Q4	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	123386	usd
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	421365	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	761509	usd
CY2023Q4	adil	Manufacturing Expenses ManufacturingExpenses	-50566	usd
CY2022Q4	adil	Manufacturing Expenses ManufacturingExpenses	-5816	usd
CY2023Q4	adil	Legal And Consulting Services LegalAndConsultingServices	5816	usd
CY2022Q4	adil	Legal And Consulting Services LegalAndConsultingServices	72616	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	477747	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	963327	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	24062	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	7942	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	32005	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
CY2023Q2	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	3000000	usd
CY2023Q2	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	500000	usd
CY2023Q2	adil	Daily Trading Value DailyTradingValue	2000000	usd
CY2023Q2	adil	Weighted Average Price Percentage WeightedAveragePricePercentage	0.95	pure
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	51901	usd
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	9123741	usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1865	usd
CY2022	adil	Common Stock Cost CommonStockCost	818350	usd
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	10000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	40000	shares
CY2023Q4	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	13335	shares
CY2023Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	26665	shares
CY2023Q1	adil	Aggregate Purchase Price AggregatePurchasePrice	750000	usd
CY2023Q1	adil	Expenses Fees ExpensesFees	609613	usd
CY2023	adil	Unregistered Share Of Common Stock UnregisteredShareOfCommonStock	7317	shares
CY2023	adil	Percentage Of Aggregate Shares PercentageOfAggregateShares	0.10	pure
CY2023	adil	Common Stock Issuances CommonStockIssuances	The Placement Agent Warrants have an exercise price equal to $10.25 and are exercisable two months after the closing date and expire five years after the date of issuance.
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	58540	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	58	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	1418440	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	3998582	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	85106	shares
CY2023Q4	adil	Exercise Price Per Share ExercisePricePerShare	3.52
CY2023	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	445440	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0788	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0189	pure
CY2023Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	39800	shares
CY2023	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	243157	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.11
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	690035	usd
CY2023	adil	Weighted Average Remaining Service Period WeightedAverageRemainingServicePeriod	P2Y10D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1746378	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3374493	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	319610	shares
CY2022	adil	Weighted Average Remaining Term Outstanding Begining Balance WeightedAverageRemainingTermOutstandingBeginingBalance	P2Y7M17D
CY2021Q4	adil	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	120.5
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	3.5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	241716	shares
CY2022	adil	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	43.5
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	74600	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.03
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	486726	shares
CY2022	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y14D
CY2022Q4	adil	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	100.75
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4347743	shares
CY2023	adil	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	1.93
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	164589	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	149.32
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	445872	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.001
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4224008	shares
CY2023	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y3M21D
CY2023Q4	adil	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	7.76
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.43
CY2023	adil	Warrants Outstanding WarrantsOutstanding	973000	shares
CY2022	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	13794	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	8000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	263195	usd
CY2023Q4	us-gaap	Derivative Underlying Investment Principal DerivativeUnderlyingInvestmentPrincipal	51.5	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.0788	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M
CY2023	adil	Warrants To Purchase Shares Of Common Stock WarrantsToPurchaseSharesOfCommonStock	445872	shares
CY2022	adil	Warrants To Purchase Shares Of Common Stock WarrantsToPurchaseSharesOfCommonStock	74600	shares
CY2023	adil	Total Proceeds TotalProceeds	502	shares
CY2022	adil	Total Proceeds TotalProceeds	1865	shares
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0369	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0485	pure
CY2023	adil	Effective Income Tax Rate Reconciliation Change In Fair Value Of Investment EffectiveIncomeTaxRateReconciliationChangeInFairValueOfInvestment	-0.0058	pure
CY2022	adil	Effective Income Tax Rate Reconciliation Change In Fair Value Of Investment EffectiveIncomeTaxRateReconciliationChangeInFairValueOfInvestment	0	pure
CY2023	adil	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionExpenses	0.0167	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0125	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0041	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0708	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0393	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2319	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1967	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12297198	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11103347	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	101758	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	157869	usd
CY2023Q4	adil	Deferred Tax Assets Restricted Stock DeferredTaxAssetsRestrictedStock	15854	usd
CY2022Q4	adil	Deferred Tax Assets Restricted Stock DeferredTaxAssetsRestrictedStock	15982	usd
CY2023Q4	adil	Deferred Tax Assets Section174 Rd DeferredTaxAssetsSection174RD	1116665	usd
CY2022Q4	adil	Deferred Tax Assets Section174 Rd DeferredTaxAssetsSection174RD	442373	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13531039	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11719187	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	437	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	384	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	437	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	384	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	437	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	384	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	NOLS generated prior to 2018 will expire in 2037 and the 20- year carryover limitation was eliminated for losses generated after January 1, 2018, giving the taxpayer the ability to carry forward losses indefinitely. However, NOL carry forward arising after January 1, 2018, will now be limited to 80 percent of Taxable income.
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions Employee Stock Ownership Plan Dividends EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends	0.50	pure
CY2023	adil	License Fees And Milestone Payments Description LicenseFeesAndMilestonePaymentsDescription	More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
CY2023	us-gaap	Royalty Expense RoyaltyExpense	40000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	40000	usd
CY2018Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.05	pure
CY2018Q2	us-gaap	Grants Receivable GrantsReceivable	1000000	usd
CY2018Q2	us-gaap	Investment Interest Rate Paid In Cash InvestmentInterestRatePaidInCash	0.50	pure
CY2018Q2	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.50	pure
CY2023	adil	Master Services Agreement Description MasterServicesAgreementDescription	The Consulting Agreement has a term of three years, unless terminated by mutual consent or by the Company for cause.
CY2023	adil	Annual Fee AnnualFee	375000	usd
CY2022Q3	adil	Annual Fee AnnualFee	430000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	435000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	416200	usd
CY2022Q4	us-gaap	Other Commitment OtherCommitment	209250	usd
CY2023	us-gaap	Other Expenses OtherExpenses	57750	usd
CY2022	us-gaap	Other Expenses OtherExpenses	151500	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Distribution Paid DeferredCompensationArrangementWithIndividualDistributionPaid	22000	usd
CY2023Q4	adil	Future Cash FutureCash	152000	usd
CY2023	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1150000	usd
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.82
CY2023	adil	Net Proceeds NetProceeds	3500000	usd
CY2023	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.125
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2300000	shares
CY2023	adil	Percentage Of Existing Warrants PercentageOfExistingWarrants	2	pure
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2022Q4	adil	Accounts Payable Related Party Currrent AccountsPayableRelatedPartyCurrrent		usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent		usd
CY2022	adil	Loss On Equity Method Investment LossOnEquityMethodInvestment		usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-10.78
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-4.91
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	1.32
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.93
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.71
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.60
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther		usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities		usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	adil	Equity Consideration Received For Sale Of Purnovate EquityConsiderationReceivedForSaleOfPurnovate		usd
CY2023Q4	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2022	adil	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionExpenses		pure
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		usd
CY2023Q4	adil	Deferred Tax Assets Rou Assets DeferredTaxAssetsROUAssets		usd
CY2022Q4	adil	Deferred Tax Assets Rou Assets DeferredTaxAssetsROUAssets		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001513525

Files In Submission

Name	View Source	Status
0001213900-24-028701-index-headers.html	Edgar Link	pending
0001213900-24-028701-index.html	Edgar Link	pending
0001213900-24-028701.txt	Edgar Link	pending
0001213900-24-028701-xbrl.zip	Edgar Link	pending
adil-20231231.xsd	Edgar Link	pending
adil-20231231_cal.xml	Edgar Link	unprocessable
adil-20231231_def.xml	Edgar Link	unprocessable
adil-20231231_lab.xml	Edgar Link	unprocessable
ea0202434-10k_adial.htm	Edgar Link	pending
ea020243401ex21-1_adialph.htm	Edgar Link	pending
ea020243401ex23-1_adialph.htm	Edgar Link	pending
ea020243401ex31-1_adialph.htm	Edgar Link	pending
ea020243401ex31-2_adialph.htm	Edgar Link	pending
ea020243401ex32-1_adialph.htm	Edgar Link	pending
ea020243401ex32-2_adialph.htm	Edgar Link	pending
ea020243401ex97-1_adialph.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0202434-10k_adial_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adil-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADIL
Adial Pharmaceuticals Inc Stock $adil

2024 Q1 Form 10-K Financial Statement

#000121390024028701 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL Adial Pharmaceuticals Inc Stock $adil

2024 Q1 Form 10-K Financial Statement

#000121390024028701 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL
Adial Pharmaceuticals Inc Stock $adil